★
Trade Filings
管理人 股票 申报文件 超级投资者
信号 机构买入 机构卖出 内部人活动 13D & 13G 监控 板块轮动
工具 股票筛选器 管理人筛选器 对比管理人 共识篮子 所有研究工具 数据 API
学习与 AI 学习 数据提问 AI 智能体
新闻 ★ 已保存
关于 关于我们 方法论 联系我们 免责声明
阅读器
数据方案

历史数据下载——随账户功能上线。

API 网关

对本站缓存数据提供免费只读JSON访问。
深色模式

🧭 引导视图
初次接触市场——对价格、收益率、年初至今涨幅、市值等概念感到陌生？我们在您浏览时以浅显易懂的方式解释每个术语，数据不变，帮助随时在线。

⚡ 专家视角
您已了解市场。只看数据——干净、快速、简洁，无多余解释。这是默认视图。

界面语言
证券记录 · 已归档季度

LLY

Eli Lilly and Company · Healthcare · Drug Manufacturers - General

1,233.5 -1.1% 市值 $1.16T 报价延迟（FMP） · 截至 Aug 25 22:08 UTC — 与下方申报数据相互独立

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024
27被追踪持有人
-3Δ持有人
329.88M持有股份
$251.63B报告持仓市值
+2新建仓位
−6清仓
Falling 确信度评分 36/100 2 被追踪股份持续上升的季度数 ●●○○○○ 计算方式说明 → 在研究台查询相关说明 →

动量输入（同类管理人）： 持有人广度 -10.0% · 股份流向 -2.5% · 净新建仓位 -14.8% — 公式
广泛派发 — 持股数量下降且持有人减少

所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025

持股变化趋势
季度持有人Δ股份报告持仓市值新增清仓
Q2 2026 193 +4 671.92M $804.91B +6 −1
Q1 2026 191 -3 666.59M $613.20B +1 −5
Q4 2025 193 +2 707.04M $758.81B +3 —
Q3 2025 27 -3 329.88M $251.63B +2 −6
Q2 2025 28 -1 307.45M $239.60B +2 −3
Q1 2025 26 0 140.32M $115.83B +1 −1
Q4 2024 26 +1 145.00M $111.91B +3 −2
Q3 2024 24 +2 109.89M $97.29B +2 —
Q2 2024 22 — 112.43M $101.75B — —
持有人数量
持有人 · Q3 2025
#管理人股份Δ股份价值其权重持有
1 The Vanguard Group ✦ (被动) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
2 The Vanguard Group ✦ (被动) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
3 The Vanguard Group ✦ (被动) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
4 The Vanguard Group ✦ (被动) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
5 The Vanguard Group ✦ (被动) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
6 The Vanguard Group ✦ (被动) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
7 The Vanguard Group ✦ (被动) 80.96M +0.7% $61.77B 0.9% ▲ Add 2 SEC ↗
8 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
9 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
10 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
11 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
12 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
13 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
14 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
15 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
16 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
17 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
18 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
19 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
20 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
21 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
22 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
23 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
24 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
25 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
26 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
27 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
28 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
29 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
30 BlackRock ✦ (被动) 65.81M -0.2% $50.21B 0.9% ▼ Trim 2 SEC ↗
31 State Street Global Advisors ✦ (被动) 34.73M +0.6% $26.50B 0.9% ▲ Add 4 SEC ↗
32 Fidelity (FMR) ✦ 24.17M -5.7% $18.44B 1.0% ▼ Trim 2 SEC ↗
33 Fidelity (FMR) ✦ 24.17M -5.7% $18.44B 1.0% ▼ Trim 2 SEC ↗
34 Fidelity (FMR) ✦ 24.17M -5.7% $18.44B 1.0% ▼ Trim 2 SEC ↗
35 Fidelity (FMR) ✦ 24.17M -5.7% $18.44B 1.0% ▼ Trim 2 SEC ↗
36 Fidelity (FMR) ✦ 24.17M -5.7% $18.44B 1.0% ▼ Trim 2 SEC ↗
37 Fidelity (FMR) ✦ 24.17M -5.7% $18.44B 1.0% ▼ Trim 2 SEC ↗
38 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
39 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
40 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
41 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
42 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
43 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
44 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
45 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
46 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
47 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
48 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
49 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
50 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
51 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
52 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
53 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
54 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
55 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
56 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
57 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
58 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
59 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
60 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
61 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
62 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
63 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
64 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
65 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
66 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
67 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
68 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
69 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
70 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
71 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
72 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
73 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
74 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
75 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
76 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
77 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
78 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
79 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
80 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
81 JPMorgan Chase ✦ 20.54M — $15.67B 0.5% n/c 1 SEC ↗
82 Geode Capital Management ✦ (被动) 19.82M +9.3% $15.07B 1.0% ▲ Add 6 SEC ↗
83 Geode Capital Management ✦ (被动) 19.82M +9.3% $15.07B 1.0% ▲ Add 6 SEC ↗
84 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
85 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
86 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
87 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
88 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
89 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
90 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
91 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
92 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
93 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
94 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
95 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
96 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
97 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
98 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
99 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗
100 Morgan Stanley ✦ 15.19M — $11.59B 0.7% n/c 1 SEC ↗

"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。

新增买入方

本季度无新增被追踪买入方。

已清仓

Norges Bank $8.83B 曾为 1.1%
Tiger Global Management $1.18B 曾为 3.5%
Viking Global Investors $325.00M 曾为 0.9%
Coatue Management $91.53M 曾为 0.3%
Duquesne Family Office $78.48M 曾为 2.0%
Renaissance Technologies $204,662 曾为 0.0%

全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 4,323 持有人, 762.84M 股份, $674.93B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。

常见共同持仓

该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。

KO27共同持有人 NVDA27共同持有人 CVS27共同持有人 META27共同持有人 WMT27共同持有人
内部人交易

公开市场买入 (P)

在我们的覆盖窗口内无内部人士公开市场买入记录。

公开市场卖出 (S)

Aug 17 Jonsson Patrik

Officer · 6.50K 股 · $7.64M

Aug 10 Zakrowski Donald A

Officer · 2.00K 股 · $2.37M

Aug 07 Hakim Anat

Officer · 5.00K 股 · $5.95M

授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论

受益所有权
Jul 23 SC 13G/A — LILLY ENDOWMENT INC

查看 SEC 原始申报文件 ↗
相关新闻
Aug 24 FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test ↗

The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…

 Forbes
Aug 24 FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly ↗

The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…

 WSJ
Aug 24 Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance ↗

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help ​identify signs of…

 Reuters
Aug 24 Eli Lilly Launches Foundayo Weight-Loss Pill in U.K. ↗

The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…

 WSJ
Aug 23 Eli Lilly launches oral weight-loss pill Foundayo in UK ↗

Eli Lilly said on Monday it has launched its oral pill, ​Foundayo, in the UK for weight ‌management and type 2…

 Reuters
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。 报告期: Q3 2025 · 方法论 · 通过API获取此数据